SGAM
PRTK

Smith Group Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Smith Group Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-72,400
Closed -$378K – 339
2020
Q2 		$378K Sell
72,400
-1,040
-1% -$4.62K 0.02% 145
2020
Q1 		$231K Sell
73,440
-3,320
-4% -$12.2K 0.01% 156
2019
Q4 		$309K Buy
+76,760
New +$266K 0.01% 165

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Smith Group Asset Management's PRTK Position: Q3 2020 in Review

Smith Group Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2020, closing a stake of 72,400 shares — an estimated $378K sold.

Smith Group Asset Management first reported a position in PRTK in Q4 2019 and held it in 3 quarters. The position peaked at $378K in Q2 2020. 100 funds tracked by Wall St. Rank hold PRTK as of Q3 2020.

  • Smith Group Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Smith Group Asset Management sold 72,400 Paratek Pharmaceuticals, Inc. shares in Q3 2020, an estimated $378K.
  • Smith Group Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2019 and held it in 3 quarters.
  • Smith Group Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $378K in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2020.

Based on Smith Group Asset Management's 13F filing for Q3 2020, filed 4 Nov 2020.